Shots:

• The US FDA has approved Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System) intended for chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)
• The approval was based on the LIFE-BTK study that assessed the Esprit BTK System & depicted reduction in disease progression plus improved clinical outcomes vs balloon angioplasty (current SoC). The results were highlighted at 35th TCT Conference in Oct 2023 & published in The New England Journal of Medicine
• The Esprit BTK System is a dissolvable stent that opens the blockage, transfers Everolimus & promotes vessel healing before dissolving. It supports the vessels for ~3yrs. enabling them to stay open independently

Ref: Abbott | Image: Abbott

Related News:- Abbott Reports Trial Results for Esprit BTK in Chronic Limb-Threatening Ischemia (CLTI)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com